Rosetta Genomics relocates CEO, expands U.S. ops

With its first diagnostic products scheduled to launch next year, Israel's Rosetta Genomics has opted to expand its U.S. operations and export CEO Amir Avniel stateside. Rosetta says the move signifies an interest in beefing up its U.S. presence while striking new collaborations and partnerships. Avniel is taking over the work done by Michael French, the president of the U.S. division who is leaving the company.

- see the release
- read the report from Globes

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.